AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
AAPL   318.25 (+0.04%)
MSFT   181.40 (-0.23%)
FB   225.46 (-1.61%)
GOOGL   1,418.24 (-0.14%)
AMZN   2,401.10 (-0.39%)
NVDA   339.48 (-0.45%)
CGC   21.72 (+9.15%)
BABA   199.49 (-0.84%)
MU   46.47 (-6.03%)
GE   6.78 (-7.00%)
TSLA   805.81 (-1.76%)
AMD   51.74 (-1.90%)
T   31.06 (-2.48%)
ACB   15.34 (+0.26%)
F   5.85 (-2.99%)
GILD   75.32 (+0.56%)
DIS   116.75 (-3.93%)
NFLX   413.44 (-1.54%)
BAC   24.86 (-4.31%)
BA   149.82 (+0.20%)
Log in

NASDAQ:GLMDGalmed Pharmaceuticals Stock Price, Forecast & News

$4.80
-0.31 (-6.07 %)
(As of 05/28/2020 04:00 PM ET)
Add
Compare
Today's Range
$4.75
Now: $4.80
$5.10
50-Day Range
$3.42
MA: $4.62
$6.08
52-Week Range
$3.02
Now: $4.80
$7.70
Volume117,661 shs
Average Volume89,269 shs
Market Capitalization$101.47 million
P/E RatioN/A
Dividend YieldN/A
Beta2.53
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. The company is develops Aramchol, an oral therapy, which is completed ARREST Phase IIb clinical study for the treatment of patients with overweight or obesity, and who are pre-diabetic or type-II-diabetic with non-alcoholic steato-hepatitis. It also evaluates Aramchol through ARRIVE Study, a proof-of-concept Phase IIa clinical trial, with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company was founded in 2000 and is headquartered in Tel Aviv, Israel.
Read More
Galmed Pharmaceuticals logo

Beat the Market (BTM) Rank

Analyst Opinion: 4.4Community Rank: 3.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.55 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GLMD
CUSIPN/A
Phone972-3693-8448

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.04 million
Book Value$3.03 per share

Profitability

Net Income$-20,460,000.00

Miscellaneous

Employees17
Market Cap$101.47 million
Next Earnings Date8/3/2020 (Estimated)
OptionableOptionable

Receive GLMD News and Ratings via Email

Sign-up to receive the latest news and ratings for GLMD and its competitors with MarketBeat's FREE daily newsletter.

Galmed Pharmaceuticals (NASDAQ:GLMD) Frequently Asked Questions

How has Galmed Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Galmed Pharmaceuticals' stock was trading at $4.21 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GLMD shares have increased by 14.0% and is now trading at $4.80. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Galmed Pharmaceuticals?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Galmed Pharmaceuticals in the last year. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Galmed Pharmaceuticals.

When is Galmed Pharmaceuticals' next earnings date?

Galmed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Galmed Pharmaceuticals.

How were Galmed Pharmaceuticals' earnings last quarter?

Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) posted its earnings results on Thursday, May, 14th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.08. View Galmed Pharmaceuticals' earnings history.

What price target have analysts set for GLMD?

9 brokers have issued 1 year target prices for Galmed Pharmaceuticals' shares. Their forecasts range from $8.00 to $29.00. On average, they expect Galmed Pharmaceuticals' share price to reach $18.63 in the next twelve months. This suggests a possible upside of 288.0% from the stock's current price. View analysts' price targets for Galmed Pharmaceuticals.

Has Galmed Pharmaceuticals been receiving favorable news coverage?

Headlines about GLMD stock have trended extremely positive this week, InfoTrie Sentiment Analysis reports. InfoTrie rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Galmed Pharmaceuticals earned a news impact score of 4.7 on InfoTrie's scale. They also assigned media stories about the biopharmaceutical company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the immediate future. View the latest news aboutGalmed Pharmaceuticals.

Who are some of Galmed Pharmaceuticals' key competitors?

What other stocks do shareholders of Galmed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Galmed Pharmaceuticals investors own include Opko Health (OPK), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Rite Aid (RAD), TherapeuticsMD (TXMD), Sorrento Therapeutics (SRNE), Micron Technology (MU), Corbus Pharmaceuticals (CRBP), Exelixis (EXEL) and Immunomedics (IMMU).

Who are Galmed Pharmaceuticals' key executives?

Galmed Pharmaceuticals' management team includes the following people:
  • Mr. Allen Baharaff, Co-Founder, CEO, Pres & Director (Age 55, Pay $784.86k)
  • Mr. Yohai Stenzler, CFO & Controller (Age 37, Pay $155.34k)
  • Mr. Guy Nehemya, Chief Operating Officer (Age 35, Pay $165.43k)
  • Dr. Liat Hayardeny, Chief Scientific Officer (Age 53, Pay $242.52k)
  • Dr. Tali Gorfine, Chief Medical Officer (Age 50, Pay $242.28k)

What is Galmed Pharmaceuticals' stock symbol?

Galmed Pharmaceuticals trades on the NASDAQ under the ticker symbol "GLMD."

Who are Galmed Pharmaceuticals' major shareholders?

Galmed Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Ibex Investors LLC (4.57%), Vivo Capital LLC (4.07%), Raymond James & Associates (1.63%), Voss Capital LLC (0.75%), Morgan Stanley (0.37%) and Phoenix Holdings Ltd. (0.36%).

Which institutional investors are selling Galmed Pharmaceuticals stock?

GLMD stock was sold by a variety of institutional investors in the last quarter, including Raymond James & Associates.

Which institutional investors are buying Galmed Pharmaceuticals stock?

GLMD stock was bought by a variety of institutional investors in the last quarter, including Vivo Capital LLC, Phoenix Holdings Ltd., Squarepoint Ops LLC, Two Sigma Securities LLC, Morgan Stanley, Ibex Investors LLC, Voss Capital LLC, and ETF Managers Group LLC.

How do I buy shares of Galmed Pharmaceuticals?

Shares of GLMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Galmed Pharmaceuticals' stock price today?

One share of GLMD stock can currently be purchased for approximately $4.80.

How big of a company is Galmed Pharmaceuticals?

Galmed Pharmaceuticals has a market capitalization of $101.47 million and generates $2.04 million in revenue each year. The biopharmaceutical company earns $-20,460,000.00 in net income (profit) each year or ($0.97) on an earnings per share basis. Galmed Pharmaceuticals employs 17 workers across the globe.

What is Galmed Pharmaceuticals' official website?

The official website for Galmed Pharmaceuticals is www.galmedpharma.com.

How can I contact Galmed Pharmaceuticals?

Galmed Pharmaceuticals' mailing address is 16 TIOMKIN STREET, TEL AVIV L3, 6578317. The biopharmaceutical company can be reached via phone at 972-3693-8448 or via email at [email protected]

This page was last updated on 5/28/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.